作者
Maria Gabriella Matera, Luigino Calzetta, Mario Cazzola
发表日期
2010/4/1
来源
Pulmonary pharmacology & therapeutics
卷号
23
期号
2
页码范围
121-128
出版商
Academic Press
简介
Tumor necrosis factor (TNF)-α, a pleiotropic cytokine that exerts a variety of effects, such as growth promotion, growth inhibition, angiogenesis, cytotoxicity, inflammation, and immunomodulation, has been implicated in several inflammatory conditions. It plays a significant role in many inflammatory diseases of lungs. Given that there is significant literature supporting the pathobiologic role of TNF-α in asthma, mainly in severe refractory asthma, and COPD, TNF-α inhibitors (infliximab, golimumab and etanercept) are now regarded as the potential new medications in asthma and COPD management. The studies reported in literature indicate that TNF-α inhibitors are effective in a relatively small subgroup of patients with severe asthma, possibly defined by an increased TNF axis, but they seem to be ineffective in COPD, although an observational study demonstrated that TNF-α inhibitors were associated with a reduction …
引用总数
20102011201220132014201520162017201820192020202120222023202491723171313188201111102133
学术搜索中的文章